No Data
Turnstone Biologics Shares Are Trading Higher After the Company Announced It Will Be Presenting Two Posters Highlighting Preclinical Data on Methods for TIL Selection at the STIC 39th Annual Meeting.
Turnstone Biologics Showcases Preclinical Data On Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy For Solid Tumors At SITC 2024, Supporting Clinical Advancement Of TIDAL-01 In Phase 1 Trials
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Turnstone Biologics Price Target Cut to $0.50/Share From $10.00 by B of A Securities
BofA Securities Initiates Turnstone Biologics(TSBX.US) With Hold Rating, Announces Target Price $0.5
Turnstone Biologics Cutting Workforce by 60%
No Data
No Data